Cilansetron

Cilansetron
Clinical data
Other names	Calmactin; KC 9946
Pregnancy; category	C;
Routes of; administration	Oral
ATC code	A03AE03 (WHO) ;
Legal status
Legal status	Unlicensed;
Pharmacokinetic data
Bioavailability	87%
Metabolism	Hepatic
Elimination half-life	1.6 - 1.9 hours
Excretion	Renal
Identifiers
	IUPAC name (10R)-10-[(2-Methyl-1H-imidazol-1-yl)methyl]-5,6,9,10-tetrahydro-4H-pyrido(3,2,1-jk)carbazol-11-one;
CAS Number	120635-74-7 ;
PubChem CID	6918107;
IUPHAR/BPS	2297;
ChemSpider	5293321 ;
UNII	2J6DQ1U5B5;
KEGG	D03495 ;
ChEMBL	ChEMBL2103778;
CompTox Dashboard (EPA)	DTXSID40152951 ;
Chemical and physical data
Formula	C20H21N3O
Molar mass	319.408 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C3c2c1cccc5c1n(c2CC[C@@H]3Cn4ccnc4C)CCC5;
	InChI InChI=1S/C20H21N3O/c1-13-21-9-11-22(13)12-15-7-8-17-18(20(15)24)16-6-2-4-14-5-3-10-23(17)19(14)16/h2,4,6,9,11,15H,3,5,7-8,10,12H2,1H3/t15-/m1/s1 ; Key:NCNFDKWULDWJDS-OAHLLOKOSA-N ;
	(verify)

Cilansetron is an experimental drug that is a 5-HT₃ antagonist under development by Solvay Pharmaceuticals.[1][2][3]

5-HT₃ receptors are responsible for causing many things from nausea to excess bowel movements. In conditions such as irritable bowel syndrome (IBS), the receptors have become faulty or oversensitive. 5-HT₃ antagonists work by blocking the nervous and chemical signals from reaching these receptors.

Studies have shown that the drug can improve quality of life in men and women with diarrhea-predominant IBS.[4] Cilansetron is the first 5-HT antagonist specifically designed for IBS that is effective in men as well as women.[4]

In 2005, Solvay received response from the U.S. Food and Drug Administration that cilansertron is not approvable without additional clinical trials;[5][6] further development has been discontinued.[7]

References

Chey WD, Cash BD (February 2005). "Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea". Expert Opinion on Investigational Drugs. 14 (2): 185–93. doi:10.1517/13543784.14.2.185. PMID 15757394. S2CID 8606399.
Olden KW, Crowell MD (October 2005). "Cilansetron". Drugs of Today. Barcelona, Spain. 41 (10): 661–6. doi:10.1358/dot.2005.41.10.920427. PMID 16389408.
Stacher G (October 2007). "Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome?". Expert Review of Gastroenterology & Hepatology. 1 (1): 15–27. doi:10.1586/17474124.1.1.15. PMID 19072430. S2CID 24301639.
General info on Cilansetron
"Solvay's cilansetron "not approvable"". PharmaTimes. April 4, 2005. Retrieved August 14, 2019.
"Calmactin Approval Status". Drugs.com. Retrieved August 14, 2019.
"Cilansetron". Retrieved August 14, 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid15757394-1] Chey WD, Cash BD (February 2005). "Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea". Expert Opinion on Investigational Drugs. 14 (2): 185–93. doi:10.1517/13543784.14.2.185. PMID 15757394. S2CID 8606399.

[pmid16389408-2] Olden KW, Crowell MD (October 2005). "Cilansetron". Drugs of Today. Barcelona, Spain. 41 (10): 661–6. doi:10.1358/dot.2005.41.10.920427. PMID 16389408.

[pmid19072430-3] Stacher G (October 2007). "Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome?". Expert Review of Gastroenterology & Hepatology. 1 (1): 15–27. doi:10.1586/17474124.1.1.15. PMID 19072430. S2CID 24301639.

[cilanserton-4] General info on Cilansetron

[5] "Solvay's cilansetron "not approvable"". PharmaTimes. April 4, 2005. Retrieved August 14, 2019.

[6] "Calmactin Approval Status". Drugs.com. Retrieved August 14, 2019.

[7] "Cilansetron". Retrieved August 14, 2019.